Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenstrom's Macroglobulinemia (WM)

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenstrom's Macroglobulinemia (WM)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zanubrutinib (Primary) ; Bendamustine; Cyclophosphamide; Dexamethasone; Ibrutinib; Rituximab
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPEN
  • Sponsors BeiGene

    • Most Recent Events

    • 12 Jul 2023 Results of final analysis reporting long-term follow-up outcomes published in the Journal of Clinical Oncology
    • 15 Jun 2023 Results assessing health-related quality of life (HRQoL) outcomes in Cohort 1, presented at the 28th Congress of the European Haematology Association.
    • 09 Jun 2023 According to a BeiGene media release, post-hoc analyses, safety pooled data from this trial will be presented at the 2023 European Hematology Association (EHA) Hybrid Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top